SG11201808524QA - Devices, systems and methods for inhibiting invasion and metastases of cancer - Google Patents

Devices, systems and methods for inhibiting invasion and metastases of cancer

Info

Publication number
SG11201808524QA
SG11201808524QA SG11201808524QA SG11201808524QA SG11201808524QA SG 11201808524Q A SG11201808524Q A SG 11201808524QA SG 11201808524Q A SG11201808524Q A SG 11201808524QA SG 11201808524Q A SG11201808524Q A SG 11201808524QA SG 11201808524Q A SG11201808524Q A SG 11201808524QA
Authority
SG
Singapore
Prior art keywords
cancer
international
street
metastases
pct
Prior art date
Application number
SG11201808524QA
Inventor
Geraldine Hamilton
Norman Wen
Catherine Karalis
Antonio Varone
Daniel Levner
Riccardo Barrile
Original Assignee
Emulate Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emulate Inc filed Critical Emulate Inc
Publication of SG11201808524QA publication Critical patent/SG11201808524QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/16—Microfluidic devices; Capillary tubes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
    • C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/02—Membranes; Filters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Clinical Laboratory Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Filing Language: (26) Publication Language: (30) Priority Data: 62/315,401 30 March 2017 (30.03.2017) English English 30 March 2016 (30.03.2016) US ( 84 ) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173066 Al 5 October 2017 (05.10.2017) WIPO I PCT 1111111111111101110101011111010111110 0101111101111101111111111111111111110111111 (51) International Patent Classification: C12M 1/02 (2006.01) Cl 2N 5/06 (2006.01) C12N 5/16 (2006.01) (21) International Application Number: PCT/US2017/024988 (22) International Filing Date: (71) Applicant: EMULATE, INC. [US/US]; 27 Drydock, Bo- ston, MA 02110 (US). (72) Inventors: HAMILTON, Geraldine, A.; 509 East 2nd Street, Unit #7, Boston, MA 02127 (US). WEN, Norman; 4975 Washington Street, Unit #18, West Roxbury, MA 02132 (US). KARALIS, Catherine; 9 Colbourn Crescent #2, Brookline, MA 02445 (US). VARONE, Antonio; 4975 Washington Street, Unit 118, West Roxbury, MA 02132 Published: (US). LEVNER, Daniel; 55 Sewall Avenue, 5C, Brook- line, MA 02446 (US). BARRILE, Riccardo; 24 Queens- berry Street, Boston, MA 02215 (US). = (74) Agent: CARROLL, Peter G.; Medlen & Carroll, LLP, 1440 Broadway, Suite 1010, Oakland, California 94612 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 1717 / 3066 Al (54) Title: DEVICES, SYSTEMS AND METHODS FOR INHIBITING INVASION AND METASTASES OF CANCER Figure 1 Source: Douglas Harahan, Robert A. Weinberg, Cancer Cal all (57) : The invention generally relates to a microfluidic platforms or \"chips\" for testing and understanding cancer, and, more specifically, for understanding the factors that contribute to cancer invading tissues and causing metastases. Tumor cells are grown on microfluidic devices with other non-cancerous tissues under conditions that simulate tumor invasion. The interaction with im- mune cells can be tested to inhibit this activity by linking a cancer chip to a lymph chip.
SG11201808524QA 2016-03-30 2017-03-30 Devices, systems and methods for inhibiting invasion and metastases of cancer SG11201808524QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315401P 2016-03-30 2016-03-30
PCT/US2017/024988 WO2017173066A1 (en) 2016-03-30 2017-03-30 Devices, systems and methods for inhibiting invasion and metastases of cancer

Publications (1)

Publication Number Publication Date
SG11201808524QA true SG11201808524QA (en) 2018-10-30

Family

ID=59960905

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808524QA SG11201808524QA (en) 2016-03-30 2017-03-30 Devices, systems and methods for inhibiting invasion and metastases of cancer

Country Status (6)

Country Link
US (3) US11970680B2 (en)
AU (1) AU2017240593A1 (en)
CA (3) CA3225255A1 (en)
GB (2) GB2564623B (en)
SG (1) SG11201808524QA (en)
WO (1) WO2017173066A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3060060B1 (en) * 2013-10-25 2019-07-03 TeVido BioDevices Tissue engineered devices and methods for making same
WO2017096297A1 (en) 2015-12-04 2017-06-08 EMULATE, Inc. Open-top microfluidic device with structural anchors
GB2573427B (en) 2016-12-02 2020-12-09 Emulate Inc In vitro epithelial models comprising lamina propria-derived cells
CA3076500A1 (en) 2017-09-21 2019-03-28 EMULATE, Inc. Rheologically biomimetic fluid surrogate
JP2021510510A (en) * 2018-01-12 2021-04-30 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー Cell reprogramming therapy
CA3089127A1 (en) * 2018-02-02 2019-08-08 Wake Forest University Health Sciences Organoids related to immunotherapy and methods of preparing and using the same
AU2019215247A1 (en) * 2018-02-05 2020-08-20 EMULATE, Inc. Stem cell-based lung-on-chip models
CN109554278A (en) * 2018-12-27 2019-04-02 上海纳米技术及应用国家工程研究中心有限公司 A kind of organ chip and the nano particle lung surface active oxidant layer interaction evaluation method based on organ chip technology
WO2020154579A1 (en) * 2019-01-24 2020-07-30 University Of Cincinnati Autologous tumor organoid and immune cell co-cultures and methods of use as predictive models for pancreatic cancer treatment
WO2020227648A1 (en) * 2019-05-09 2020-11-12 EMULATE, Inc. Compositions and methods of using partial gel layers in a microfluidic device
CN110106081B (en) * 2019-05-13 2022-10-14 大连医科大学附属第一医院 Micro-fluidic chip for constructing brain function unit model and construction method
WO2022039584A1 (en) * 2020-08-18 2022-02-24 연세대학교 산학협력단 Cancer cell transformation observation system using circulation-type cancer cell transformation measuring device and device for collecting transformed cancer cells comprising artificial blood vessel unit
KR102507881B1 (en) * 2021-01-11 2023-03-07 전남대학교산학협력단 3 dimension microfluidic system and bio-controlled protein analytical method using of the same
EP4366873A1 (en) 2021-07-08 2024-05-15 Ourotech, Inc. Treatment efficacy prediction systems and methods
WO2023282925A1 (en) * 2021-07-08 2023-01-12 Ourotech, Inc. Treatment efficacy prediction systems and methods
WO2023192663A1 (en) * 2022-04-01 2023-10-05 University Of Cincinnati Rapid 3d-bioprinting of microfluidic vascular tissue models
CN116539862B (en) * 2022-07-20 2024-03-12 成都诺医德医学检验实验室有限公司 Method for testing tumor metastasis capability based on organoid symbiotic long platform

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015204375A1 (en) * 2008-07-16 2015-08-06 Children's Medical Center Corporation Organ mimic device with microchannels and methods of use and manufacturing thereof
CN104328050B (en) 2008-07-16 2017-12-15 儿童医疗中心有限公司 Organ with microchannel imitates device and its use and manufacture method
WO2010132537A1 (en) 2009-05-13 2010-11-18 The Regents Of The University Of Michigan Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
SG10201508047SA (en) * 2010-09-29 2015-10-29 Massachusetts Inst Technology Device for high throughput investigations of cellular interactions
EP3498818A1 (en) * 2011-02-28 2019-06-19 President and Fellows of Harvard College Cell culture system
US10087422B2 (en) 2011-12-09 2018-10-02 President And Fellows Of Harvard College Organ chips and uses thereof
US9725687B2 (en) 2011-12-09 2017-08-08 President And Fellows Of Harvard College Integrated human organ-on-chip microphysiological systems
US20130236972A1 (en) * 2012-03-07 2013-09-12 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Liver Sinusoid Model
EP3083940A4 (en) 2013-12-20 2017-08-23 President and Fellows of Harvard College Low shear microfluidic devices and methods of use and manufacturing thereof
US20160326477A1 (en) * 2013-12-20 2016-11-10 Jose FERNANDEZ-ALCON Organomimetic devices and methods of use and manufacturing thereof

Also Published As

Publication number Publication date
GB2600648B (en) 2022-08-10
US20170285003A1 (en) 2017-10-05
GB201817471D0 (en) 2018-12-12
GB2564623A (en) 2019-01-16
US11970680B2 (en) 2024-04-30
AU2017240593A1 (en) 2018-11-01
GB202201778D0 (en) 2022-03-30
CA3205061C (en) 2024-02-13
US20220282194A1 (en) 2022-09-08
WO2017173066A1 (en) 2017-10-05
CA3019540C (en) 2023-09-05
CA3205061A1 (en) 2017-10-05
CA3225255A1 (en) 2017-10-05
US11371000B2 (en) 2022-06-28
GB2600648A (en) 2022-05-04
US20190119618A1 (en) 2019-04-25
GB2564623B (en) 2022-03-30
CA3019540A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
SG11201808524QA (en) Devices, systems and methods for inhibiting invasion and metastases of cancer
SG11201804372PA (en) Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201900274VA (en) Event trigger for independent links
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201407200TA (en) Liquid formulation
SG11201407873RA (en) Endoscopic sympathectomy systems and methods
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201804916PA (en) Three-dimensional polymer networks with channels situated therein
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201908075UA (en) A microneedle device
SG11201407790SA (en) Methods and systems for gas lift rate management
SG11201804770QA (en) Method and arrangement for recovery of salt
SG11201810196RA (en) Cancer treatments
SG11201908929VA (en) Synthekine compositions and methods of use
SG11201808675VA (en) Method and kit for the generation of dna libraries for massively parallel sequencing